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A B S T R A C T
Synchrotron radiation circular dichroism (SRCD) is a powerful tool for photo-stability assessment of
proteins. Recently our research has been interested in applying SRCD to develop screeningmethodologies
for accelerated photo-stability assessment ofmonoclonal antibody formulations. Despite itwas proven to
be reliable and applicable within a wide range of salts and excipients containing solutions, the presence
of far-UV (<260nm) strong absorbing species (e.g., sodium chloride, histidine, arginine) in common
formulations completely prevent the analysis. Herein, we propose a new method based on CD coupled
with magnetic CD (MCD) to address the problem and offer an additional versatile tool for monitoring the
photo-stability. This is done by assessing the stability of the samples by looking at the near-UV band, as
well as giving insights in the denaturation mechanism. We applied this method to four mAbs
formulations and correlated the results with dynamic light scattering data. Finally, we applied MCD in
ligand interaction to key proteins such as lysozyme, comparing the human with the hen enzyme in the
binding of N,N0,N0 0-triacetylchitotriose.
ã 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Among the factors affecting protein stability, light exposure is a
major issue for bio-pharmaceutics development. Light exposure
leads to denaturation and degradation and eventually loss of
activity. The optimisation of a methodology of stability assessment
including fast and reproducible photo-stability is therefore a
requirement. Light sources with constant and controlled photon-
ﬂux and with precise and tuneable emission spectrum would be
required to ensure reproducibility and reliability. In these respects,
the high photon-ﬂux available at synchrotron radiation circular
dichroism B23 beamline (Diamond Light Source Ltd., Didcot,
Oxfordshire) represents a resourceful innovation for bio-formula-
tion stability assessment. Moreover, circular dichroism (CD) is able
to give direct information on secondary structures which exhibits
characteristic signatures in the farUV (below 260nm) (Greenﬁeld,
2006; Kelly et al., 2005). However, the farUV range is sometime un-
accessible, particularly in presence of high salt (e.g., chloride)
concentration and excipients, such as guanidinium derivatives
(e.g., arginine) and histidine with high absorption in the far-UV
(<250nm). Nonetheless, proteins present other absorptions that
could account for changes in the structure. The 260–320nm CD
bands due to aromatic side-chains (mostly tryptophans and
tyrosines) and disulphide bonds are exploited to assess changes
occurring in the tertiary structure due to either the presence or
absence of rotational freedom of the aromatic side-chain causing
decreased or increasing the optical activity respectively. Both can
contribute to the overall intensity of the CD spectrum. Comple-
mentary to circular dichroism, magnetic circular dichroism (MCD)
is a related technique where the optical transitions are induced by
an external magnetic ﬁeld (Faraday effect). MCD has been widely
applied in the study of porphyrines, (Kalman et al.,1973; Kobayashi
and Nakai, 2007) paramagnetic metal complexes, (Barrett et al.,
1986; Modine et al., 1971) metal nano-particles, (Zaitoun et al.,
2001) other biological relevant organics, (Voelter et al., 1968)
indole derivatives, (Albinsson et al., 1989; Sprinkel et al., 1975)
haem, (Brittain et al., 1978; Pond et al., 1999a,b,c,c) and proteins
(Barth et al., 1971, 1972b; McFarland and Coleman, 1972). For
proteins in particular, tryptophan residue has beenwidely targeted
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for MCD investigations. Notably, the 293nm positive contribution
in the near-UV region is mainly due to tryptophan contributions,
with negligible opposite contributions due to the 275nm tyrosine
band, and it has been shown to display low dependency on the
tertiary structure (Barth et al., 1971). Only above 15/1 ratio
between tyrosine and tryptophan the 293nmpeak is distorted by a
negative contribution from tyrosine (Barth et al., 1972b). However,
corrections can be taken into account since all these contributions
are linearly combined. The possibility to detect tryptophan in
proteins independently by conformations can be applied using
MCD for the evaluation of the overall protein concentration as
reported by Barth et al. (1971, 1972a,b),),). A similar aim for MCD
has been already employed with uro-porphyrines (Kalman et al.,
1973).
Here, we demonstrate the application of MCD to assess proteins
photo-stability of cetuximab, a monoclonal antibodies, in combi-
nation with CD in the near-UV giving useful information on the
behavior of bio-pharmaceutical upon light exposure. First, we will
apply MCD for determining the tryptophan content and exposure
to solvent, applying it on several commercialised model proteins,
such as hen egg lysozyme, human serum albumin, bovine serum
albumin, myoglobin and human serum immunoglobulin G,
concanavalin A, a-lactalbumin and avidin, in comparison with
the effects of denaturants. Then, wewill apply it to the detection of
the effects of light exposure, comparing the MCD results with the
CD and dynamic light scattering. Finally, we will show how MCD
could complement CD measurements to account for binding
interactions between a protein and ligands. In particular, we chose
the binding of hen lysozyme to N,N0,N0 0-triacetylchitotriose (NAG),
an inhibitor of enzymatic activity towards the cleavage of
glycosidic bonds.
2. Materials and methods
2.1. Samples preparation
5mL of a solution of cetuximab (commercial name Erbitux) has
been dialyzed using Pur-A-LyzerTM G2 (Sigma–Aldrich) dialysis
tubes for 24h in water. The solution was then concentrated using
Vivaspin 500, 3–5kDa MWCO (GE) in a centrifuge (21,000 rpm,
15min). The concentrated solutions (about 40–50mgmL1) were
then diluted in the chosen buffers to a concentration of 1–
1.5mgmL1. Hen egg lysozyme (Sigma L6876), human serum
albumin (HSA, Sigma A3782), bovine serum albumin (BSA, Sigma
A9085), equine skeletal muscle myoglobin (Sigma M0630) and
human serum immunoglobulin G (IgG – Sigma I4506), concanav-
alin A (Type VI, Sigma L-7647), a-lactalbumin (Type III, Sigma L-
6010) and avidin (Sigma A-6128) and human lysozyme (Sigma L-
1667) were stored at 20 C before use. N,N0,N0 0-
triacetylchitotriose was purchased by Sigma (90,251 Fluka). All
measurements were recorded in water and concentrations
measured either with Bradford assay and absorbance measure-
ment (e280nm =150,000, 36,000, 35,700, 43,824, 13,980, 210,000,
35,034, 29,642, 94,460mol1 L cm1 respectively) employing an
IMPLEN nanophotometer P330. Salts for excipient preparation
were bought from Sigma. Tween1 20 was bought from Thermo
Scientiﬁc.
2.2. Bradford assay
The Bradford test (BT)was performed on a Perkin Elmer Lambda
950 UV/VIS spectrometer equipped with a PTP 1+1 Peltier system
with bovine serum albumin (BSA) and bovine g-globulin (BGG)
standards purchased from Fisher Scientiﬁc. Coomassie Blue G-250
1X solutionwas purchased from Fisher Scientiﬁc and was added to
each standard of required concentration, mixing vigorously,
equilibrating for 5–10min at room temperature, centrifuging
and reading the absorbance at 595nm (1 cm plastic cell, 25 C).
Each measurement was repeated in quadruplicate with a 1 cm
disposable plastic cell on four different solutions. All the spectra
were subtracted from the baseline (Coomassie 1X at the same
concentration in water). The results were compared with an
absorbance reading at 280nm.
2.3. CD and MCD
Magnetic circular dichroismmeasurements were performed on
the OLIS module B unit at B23 beamline at Diamond Light Source,
Harwell Research and Innovation Campus, Didcot, Oxfordshire, UK.
For UV-denatured samples the CD spectra were collected on an
applied photophysics Chirascan Plus spectropolarimeter equipped
with a ﬂuorescence detector. Themodule BOLIS instrument for CD/
MCD was provided with a sample chamber room able to support a
1.4 T OLIS magnet. The spectra for model proteins were recorded in
the 340–260nm wavelength range, with a 1 cm quartz cell. For
photo-denaturation samples, the spectra were collected in a 1 cm/
100mL cell. A 1mm or 0.5mm slit were employed with 1 sec of
integration time. MCD spectra were recorded in both ﬁeld
directions (N/S and S/N), subtracted (S/N–N/S) ensuring a positive
value at 293nm. Spectra are reported un-corrected for the ﬁeld
magnitude.
2.4. Sample irradiation
Controlled photo-denaturation of samples were performed
with a Peqlab box, equipped with ﬁve 60W lamps emitting at
254nm. The mAbs were irradiated at 0.7mg.mL1 concentration
solution (concentration measured with Bradford test and
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Fig.1. (a) MCD of IgG 1mgmL1 water, guanidinium 6Mor urea 8M. (b)MCD of BSA 2.4mgmL1 water, guanidinium 6Mor urea 8M.1 cm cell, 4 scans. Spectra divided by 2.
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absorbance at 280nm) in a 0.5mm path length quartz cell, and the
liquid exposed an overall surface of 3 cm2.
2.5. Dynamic light scattering
DLS measurements have been performed on a Malvern
Zetasizer Nano. The measurements have been performed on
0.68mgmL1 samples with plastic cuvette, 50mL of solution. The
measurements size quality reports were always reported as good
and therefore the evaluation of hydrodynamic radius acceptable.
3. Results and discussion
3.1. MCD spectra of proteins in the near-UV. Dependence on
tryptophan exposure and measuring of tryptophan content
As introduced earlier, MCD haswidely been applied to the study
of several systems, such as porphyrins, haems, metal complexes
and proteins. Tryptophan, endowed with a MCD active probe
(indole), has constituted a suitable target for MCD study of
proteins. To prove the reliability of this residue as a probe, several
proteins of known sequence were selected and their concen-
trations determined by measuring the MCD. MCD protein
concentration evaluation relies on tryptophan residue in proteins.
Water exposure or electron withdrawal moieties can affect the
peak position and intensity, inducing blue-shift and reduce the
spectral intensities. For example, we measured the effect on the
MCD of IgG and BSA in two denaturant, urea and guanidinium
(Fig. 1) widely used in protein biopharmaceutical expression and
puriﬁcation conditions.
The denaturants affect the MCD spectra with an overall loss of
intensity and blue-shifting. Nonetheless, the spectra of the
denatured samples are only slightly affected by the nature of
the denaturants, with a major effect on the tyrosine band at
275nm. The near-UV CD spectrum of BSA in presence of
denaturants is also given for comparison (SI, Figure 1). The MCD
spectrum is more informative, speciﬁcally in the 293nm region. In
the same conditions the MCD spectra are more intense and less
noisy than CD, increasing the chance of application of MCD for
analytical detection of tryptophan in protein even a lower
concentrations. Moreover, for MCD the loss of conformation has
a smaller inﬂuence on the spectra whereas the change is probably
due mostly to the exposure of the tryptophan to the solvent only.
Brieﬂy, the lmax values for MCD of some of the investigated
proteins are reported in Table 1.
All the values are close to 293nm for all the proteins under
investigation, except for IgG that is even red-shifted to 294nm. For
more exposed tryptophan (with denaturants) the value shifts
towards 290nm, as had been found for N-Ac-(L)-Trp-OMe, which
can be viewed as a completely water-exposed indole (Barth et al.,
1971). Noticeably, all the proteins investigated here and inprevious
works show a lmax at 293–294nm, suggesting that tertiary
structure has little or even negligible inﬂuence on the spectrum.
This is in agreement with most of the known protein sequences
(Barth et al., 1972b; McFarland and Coleman, 1972; Vitale et al.,
2000). To validate the method, several proteins such as hen egg
lysozyme, human serum albumin, bovine serum albumin,
Table 1
lmax for the MCD of selected proteins and conditions.
lmax MCD
Lysozyme 293
Myoglobin 293
BSA 293
BSA (urea 8M) 292–293
BSA
(guanidinium.HCl 6M)
292–293
HSA 293
IgG 294
IgG (urea 8M) 292
IgG
(guanidinium.HCl 6M)
292
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Fig. 2. MCD spectra of some model proteins and peptides. Measurements recorded
at 23 C, 1 cm path length, 4 scans with 0.5 nm increment and 1 s integration time.
Concentrations evaluated by simple dilution of the commercial proteins. Spectra
divided by 2.
Table 2
MCD evaluation of Trp contents and concentrations.
Theoratical conc.
(mgmL1)
Abs evaluated conc.
(mgmL1)
Bradford assay (mgmL1)c u293 nm
(mdeg)
Evaluated
number
of Trpa
MCD conc.
(mgmL1)
(A)
Lysozyme 0.40 0.34 0.11  0.02 18.20 5.10 0.36
BSA 1.95c 1.27 1.95  0.08b 6.46 2 1.95
HSA 3.00 1.53 2.42  0.01b 2.49 0.86 1.67
Myoglobin 0.98 0.77 0.87  0.09 9.73 2.74 0.69
IgG 0.50 0.44 0.22  0.04 6.09 2.11 1.55
Concanavalin A 0.60 0.53 0.10  0.03 8.46d 2.40 0.45
a-Lactalbumin 0.40 0.36 0.26  0.09 10.1 2.85 0.40
Avidin 0.60 0.54 0.37  0.12 14.85 4.15 0.49
a Correction factor applied (see SI).
b Measured from a 1:4 based diluted solutions.
c Measured with the BT.
d Maximum at 292.5 nm.
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myoglobin and human immunoglobulin G was tested (Fig. 2). The
concentrations employed were chosen to provide a UV absorbance
close to 0.8 at the maximum of absorbance wavelength (usually
285–290nm).
All the main positive peaks are located at 293–294nm, with the
maximum red-shift for IgG. Conversely, concanavalin A shows a
marked blue-shift, with the main peak position at 292nm. In fact,
the presence of exposed tryptophan residues in concanavalin A had
already been reported (Mandal and Mandal, 2011; Pelley and
Horowitz, 1976). In Table 2, tryptophan content was estimated
following a previously reported method (Barth et al., 1972a,b,b).
Nonetheless, since the exposure of tryptophan to solvent can bias
considerably the 293nm peak position and intensity (a lmax of
290nm is reported for N-Ac-(L)-Trp-OMe), we employed BSA as a
reference sample, allowing also a further cross-checking with the
Bradford test. As a correction for the negative contributions given
by high tyrosine/tryptophan ratios, we corrected the evaluated
tryptophan content as reported by Barth et al. (1972b). They
evaluated a change of the 1% at 293nm for a 1:1 ratio tyrosine/
tryptophan, and 40% for a 35/1 ratio. They also reported a
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Fig. 3. (a) Near-UVMCD spectrum of cetuximab 0.68mg/mL in acetate buffer 20mM pH 5.0 with 0.1% Tween 20; (b) near-UVMCD spectrum of Cetuximab 0.68mg/mL in His
20mM pH 6; (c) near-UV MCD spectrum of cetuximab 0.68mg/mL in PBS 20mM pH 6.0 with Arginine 200mM. 4 scans averaged, 1mm slit, 1 nm/s scan rate. 7 points-2nd
polynomial order SG smoothing applied. (e) Plot of decay rates monitored at 294m. No ﬁtting applied.
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correction factor dependent on the ratio between the intensities at
275 and 293nm. The correction curve is reported in SI and it is
explained thoroughly. Other contributions in this region (as for
example the Myoglobin heme) prevent only few cases from awide
application of this method for concentration determination, in
particular when neither the Bradford test nor the absorbance can
be employed. We ﬁrstly applied it to correct the tryptophan
content for BSA (|u293nm|/|u275 nm|). The full calculation along with
the Bradford Test results is reported in SI.
The calculation correlates the ellipticity at 293nm with the
protein concentration through a simple relation reported in SI. The
application of this method implies that (i) the tryptophan
contributions are simply additive, (ii) the average single trypto-
phan contribution for different folded proteins is the same, (iii) the
BSA concentration has to be evaluated by other accurate mean
(Bradford Test in our case). The ﬁrst assumption is meant for
solvent unexposed tryptophan residues. This is easily checked for
our model proteins, since all have a lmax above 293nm (in some
cases even above 295nm). The presence of strong denaturants that
would expose the aromatic residues to solvent would shift the
band down to 292nm as showed before. The second assumption
takes into account that the tryptophan contributions are the same
for folded proteins since they are not affected by the conformation.
The only correction made to the model was to introduce the
correction based on the tyrosine/tryptophan ratio. Finally, we took
the BSA ellipticity weighted for each tryptophan contribution and
concentration (calculated for BSA only considering the Bradford
assay measure for concentration) as a reference. Otherwise, for all
the other proteins, the absorbance evaluated concentration is in
good agreement with the MCD evaluation, so conﬁrming the
goodness of the Bradford test. A discrepancy of the Bradford Test
with respect to the absorbance and MCD evaluation was found for
concanavalin A. Similarly, disharmony was found in the results for
IgG and myoglobin. This may be due to the underestimation of the
tryptophan content in the case of IgG and contribution of the haem
absorptions at 293nm for myoglobin. The results, even restricted
to few model proteins, are sufﬁcient to envisage an expansion of
MCD application to other protein systems. MCD could provide a
complementary spectroscopic method to cross-check protein
sample concentrations, in particular when other methods are
un-applicable. It is material saving and does not require any
particular sample preparation (as with the Bradford Test),
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Fig. 5. MCD titration at increasing volumes on hen egg lysozyme (0.4mg/mL) (left) and human lysozyme (0.4mg/mL) (right). Titration points referred to equivalents of N,N0 ,
N0 0-triacetylchetotriose (stock concentration 1.054mg/mL) added to solution. 8 scans, 0.5 nm increments, 0.5 nm/s, 0.5 nm bandwidth. Inset: expansion of the 293–294nm
main positive peaks. (c) First derivative spectra of 5a, d) ﬁrst derivative spectra of 5b. Spectra divided by 2 and corrected for dilution factor.
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requiring only to detect by other means the concentration of a
reference standard (BSA in our case) such as the standards
provided for Bradford Test commercial kit.
3.2. Monitoring the photo-denaturation by MCD/CD comparison for
three mAbs formulations
The high photon-ﬂux available at B23 beamline (Diamond Light
Source Ltd., Didcot, Oxfordshire) allows direct measurement of
proteins photo-denaturation by measuring synchrotron radiation
circular dichroism (SRCD) spectra (Hussain et al., 2012a,b,b). The
high photon-ﬂux of the light beam generated by the synchrotron
can be exploited to induce photo-denaturation of proteins and at
the same time employed for spectroscopic analysis, such as
recording CD spectra, allowing a versatile tool to monitor the
change in secondary structure associated with the denaturation.
Even though far-UV SRCD has been the major tool to assess photo-
stability, in some cases this technique is not applicable (e.g., high
salt concentration in the buffer). Moreover, the low dependence of
the MCD upon small conformational changes may result useful to
discriminate the protein unfolding due to back-bone denaturation
vs photo-degradation of the aromatic content. We selected
cetuximab, an IgG1 monoclonal antibody approved by FDA for
treatment of some cancers such as colorectal cancer, head and neck
cancer, in four different formulations, monitoring the effect of
irradiation with MCD. We studied two formulations in particular
that contains amino acids (as excipients) that absorbs light below
250nm (Fig. 3b and c), preventing secondary structure analysis.
Other formulations are transparent in the far-UV. Formulation 5a
(Acetate 20mM with PS20 0.1%) shows marked instability in the
denaturation experiments. Conversely, the fourth formulation is
the most stabilising for cetuximab. So, the comparison among the
four formulations may lead to a comparative tool with far-UV
denaturation and givemore insights in photo-stability. In Fig. 3 the
MCD spectra for cetuximab in the four studied formulations have
been reported.
As expected, the four formulations display different denatur-
ation rates. In particular, the fourth (Acetate/PS20/Sorbitol) shows
slower degradation as already observed in the far-UV CD spectra.
Notably, the overall higher stability of the fourth formulation is
present in both the two major contributions (tryptophan 294nm
band and tyrosine 275nm band). The fourth and the ﬁrst
formulations share many constituents except sorbitol which could
induce stabilisation to cetuximab against the effect of light. Its role
in preventing denaturation effects for biopharmaceuticals and
biological materials in general had been already reported (Chang
et al., 2005; Gonzalez et al., 1995), but it was not previously
reported in particular for photo-stabilisation. However, aggrega-
tion/precipitation phenomena associated with the denaturation
cannot be ruled out and the effect of the sorbitolmay be preventing
these phenomena. Dynamic light scattering (DLS) suggested that
bigger but still stable aggregates are formed, as indicated by the
increased hydrodynamic radius but very low polydispersity at 6 J
irradiation (SI, Table 4–7). This may suggest that the antibodies
tend to generate stable agglomerates, possibly in order to prevent
the hydrophobic cores to be exposed, as conﬁrmed lmax at 294nm
which does not change even after a long exposure. Sorbitol may
play a major role in driving this process, since it is the only
excipient present in the two most stable formulations, but this
hypothesis will require to be tested.
Parallel to MCD we monitored the decaying trends via near-UV
CD measurements in the same range and in the same conditions
employed for MCD. The near-UV CD decaying plot are reported in
Fig. 4.
Almost all the considerations made for the MCD decay plot can
be observed here. However, the CD in the near-UV arises from the
local tertiary structure surrounding the chromophores (trypto-
phans and tyrosines). Notably, the CD intensity at 294nm for the
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Fig. 6. CD titration experiment of 1.5mL (upper-left). Hen egg lysozyme 0.4mgmL1 inwater (upper-right). Human lysozyme 0.4mgmL1 inwater, with NAG 1.054mgmL1.
Measurements corrected for the dilution factor and subtracted of the buffer/ligand contributions. CD titration plot expressed in DA (lower-left). Hen egg lysozyme
0.4mgmL1 in water (lower-right). Human lysozyme 0.4mgmL1 in water, with NAG 1.054mgmL1. The data were analysed with CDApps software (Siligardi et al., 2002).
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Acetate/PS20 formulation initially increases slightly in conse-
quence of the irradiation, whereas it decreases for the other two
(histidine and phosphate–arginine formulations). This fact can be
explained by an increased initial adjustment in the structure
induced by the irradiation, followed by a loss of secondary
structure that could be regarded as the reason for the further
aggregation observed in the DLS.
3.3. MCD of Lysozyme titration with N,N0,N0 0-triacetylchitotriose
NAG is an inhibitor of the glycolysis activity of lysozyme. The
interaction of the binder to the enzyme causes structural
modiﬁcations to the protein and deactivation (Cheetham et al.,
1992; Mine et al., 2000). MCD measurements have been exploited
to determine whether the interaction of lysozyme with NAG
inhibitor could induce any change to the MCD spectra. The results
are reported in Fig. 5.
The absence of dramatic changes in the MCD indicates that the
binding does not affect the exposure to buffer of the aromatics
involved. Conversely, the great change in the CD (Fig. 6) accounts
for tertiary structure change caused by the binding that has already
been described (Blake et al.,1967;Mine et al.,1999). It is relevant to
note that the binding does not affect peak intensity of the 293nm
MCD band, conﬁrming that conformational changes alone do not
modify the MCD of buried residues. For the titration of hen egg
lysozymewithNAG, themain positive peak shows a neat shift from
293.3 to 293.7 nm. This trend is absent with human lysozyme,
apart from an initial red-shift upon addition of the ﬁrst amount of
ligand. The lmax shifting for hen egg lysozyme indicates that the
binding to the ligand increases the shielding of the aromatic from
the solvent. The curves for 1:1 and 1:2 ratio perfectly overlaps,
suggesting that all the binding sites are already bound to NAG and
the addition of ligand does not induce any further change. The
discrepancies between the two spectra account mainly for the
different amino acid composition in the binding site. In fact, NAG
binds to a tryptophan in the hen egg lysozyme and to a tyrosine in
the human lysozyme (Mulvey et al., 1973, 1974). The ﬂuorescence
and CD titration plot and spectra (Fig. 6 and Fig. 7) are reported.
The evaluated dissociation constant for hen egg lysozyme is
5mM. For human lysozyme the evaluated kd is 46.8mM.
The binding of NAG to human lysozyme does not involve a
tryptophan (tryptophan-62) such as for hen lysozyme, as indicated
by the different change in the CD and the ﬂuorescence spectra. In
fact, in the human version the site is point mutated with a tyrosine
residue. In the CD the main changes are present at 293nm for hen
lysozyme and 275nm for human lysozyme, in agreement with the
different residue that they bind. In the case of the ﬂuorescence, the
binding to the hen lysozyme induces a peak blue-shift and
increasing intensity that is compatible with the binding of a
tryptophan and an increasing hydrophobicity (Mulvey et al., 1973).
Conversely, in the case of the human lysozyme there is only a
raising of the spectrum intensity, probably due to the conforma-
tional rearrangement. This approach would eventually allow
selective investigations of protein–ligands interactions involving
aromatic residues in the binding.
4. Conclusions
We showed a coupled CD/MCD application for the investigation
of biopharmaceuticals formulation photo-stability and binding
interactions. MCD had previously been as an alternative method
for concentration assessment as demonstrated showing indepen-
dence to conformational arrangement. This allows an accurate
evaluation of tryptophan content and concentration from evalua-
tion of 294nm tryptophan contribution. The method showed few
discrepancies from the classic absorption and Bradford Test
concentration evaluation. MCD can be a useful supplementary
tool for assessing the concentration of protein samples with highly
absorbing additives or excipients that are not suitable for the
Bradford Test analysis. Furthermore, MCD is useful in UV
denaturation rate assessment or photostability pertinent in
biopharmaceutical characterisation, to assess protein stability
such as mAbs formulations. This allows correlation of effects of
different buffers/excipients to changes in MCD with the aggrega-
tion effects supported by DLS which can further be extended to
correlate with immune-activity assay and other aggregation
assays. MCD can also be employed in discriminating aromatic
residues involve in ligand binding as shown in aromatic residue
preference of NAG to human and hen lysozyme. For human
lysozyme the change is mainly located in the tyrosine band
(275nm) and no neat shift is observed for the 293 peak. For hen
lysozyme, a 1nm red shift in the maximum peak position
tryptophan (293–294nm) is an indication that the ligand binds
the residue. In summary, MCD coupled with CD and ﬂuorescence
or other biophysical techniques can be a useful tool in biopharma-
ceutical characterisation.
Acknowledgment
The authors thank Dr. Renato Schiesari (University of Padova –
Italy) for the kind support in the acquisition of MCD spectra of
lysozyme.
[(Fig._7)TD$FIG]
300 320 340 360 380 400 420
0.00
0.05
0.10
0.15
0.20
0.25
Hen Egg Lysozyme/NAG
Fl
uo
re
sc
en
ce
Wavelength (nm)
1:0
1:0.5
1:1
1:2
300 320 340 360 380 400 420
0.00
0.05
0.10
0.15
Fl
uo
re
sc
en
ce
Human Lysozyme/NAG
Wavelength (nm)
1:0
1:0.5
1:1
1:2
Fig. 7. Fluorescence titration experiment of 1.5mL (left). Hen Egg Lysozyme 0.4mgmL1 in water (right). Human Lysozyme 0.4mgmL1 in water, with NAG 1.054mgmL1.
Measurements corrected for the dilution factor. lexc = 280nm, Dlexc = 8nm, 1 scans, 1 nm/s. Data are un-calibrated for external references.
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Appendix A. Supplementary data
Supplementary data associatedwith this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.
ijpharm.2015.01.026.
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